Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia

NCT02745223 | Completed Phase 2 DMC

• 1 other identifier: FG-PRE-101
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

A study to establish safety, tolerability, and efficacy of PresbiDrops (CSF-1) in presbyopic subjects.

Conditions

Presbyopia

Outcome Measures

Primary Outcomes (2)

• Percentage of participants with a ≥ 2 line improvement from Baseline in uncorrected near distance visual acuity

  Uncorrected visual acuity will be assessed at distance and near (40 cm) using a standardized eye chart. The number of lines in the eye chart that the participant correctly identifies will be measured. The test will be performed both binocularly and on 1 eye at a time by covering the eye not being tested. Distance visual acuity will be measured under normal light conditions. Near acuity will be measured both in poor light conditions and normal light conditions.

  Baseline to end of treatment (up to 14 days)

• Mean change from Baseline in the number of lines correctly identified in uncorrected near distance visual acuity

  Uncorrected visual acuity will be assessed at distance and near (40 cm) using a standardized eye chart. The number of lines in the eye chart that the participant correctly identifies will be measured. The test will be performed both binocularly and on 1 eye at a time by covering the eye not being tested. Distance visual acuity will be measured under normal light conditions. Near acuity will be measured both in poor light conditions.

  Baseline to end of treatment (up to 14 days)

Secondary Outcomes (8)

• Percentage of participants with a ≥ 2 line improvement from Baseline in uncorrected intermediate distance visual acuity

  Baseline to end of treatment (up to 14 days)

• Mean change from Baseline in the number of lines correctly identified in uncorrected intermediate distance visual acuity

  Baseline to end of treatment (up to 14 days)

• Change from Baseline in the depth of focus at distance and near

  Baseline to end of treatment (up to 14 days)

• Change from Baseline in uncorrected distance visual acuity

  Baseline to end of treatment (up to 14 days)

• Change from Baseline in the need for glasses

  Baseline to end of treatment (up to 14 days)

Study Arms (2)

PresbiDrops (CSF-1)

EXPERIMENTAL

Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.

Drug: PresbiDrops (CSF-1)

Placebo

PLACEBO COMPARATOR

Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.

Drug: Placebo

Interventions

PresbiDrops (CSF-1) DRUG

PresbiDrops (CSF-1) is a topical ophthalmic drug.

PresbiDrops (CSF-1)

Placebo DRUG

Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.

Placebo

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women between 40 and 65 years of age (inclusive).
• Subjects who provide written informed consent to participate in the study.
• Subjects have signs of presbyopia upon ophthalmic examination.
• Subjects have normal presbyopia with low distance refraction (sphere no greater than ±0.75 diopter cylinder no greater than ±0.75 diopter cylinder \[DC\], refraction along any principal meridian no greater than 1.00 diopter).
• Subjects must have best corrected vision of 20/20 in both eyes, and currently depend on reading glasses or bifocals in which the near addition is \> +1.00 diopter.
• Subjects in general good health in the opinion of the Investigator as determined by medical history.
• Women with childbearing potential must have a negative urine pregnancy test at Screening and be willing and able to use a medically acceptable method of birth control or they must be postmenopausal. Acceptable methods of birth control in this study include: Vasectomy, tubal ligation, consistent use of an approved oral contraceptive (birth control pill), intrauterine device (IUD), hormonal implants, contraceptive injection or a double barrier method (diaphragm with spermicidal gel or condom with contraceptive foam). Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.
• Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study.

You may not qualify if:

• History of macular disease or any other ocular conditions or congenital malformation.
• Any medical condition known to affect the structure of the uvea, cornea, lens, or retina or main function of the eyes.
• No cataract or minimal nuclear sclerosis.
• Severe dry eye.
• Any topical ophthalmic medications, other than artificial tears (up to a maximum of 4 times per day) and medications that are associated with fluctuation of accommodative capacity and/or pupil size, unless on a stable dose for at least 3 months before the Screening visit.
• Contact lenses for the past three months before the Screening visit.
• A difference of more than 0.50 diopter between the manifest spherical equivalent and the wave front refraction spherical equivalent.
• Pupil size less than 2,5 mm in either eye prior to dilation at ambient light of 8-15 lux prior to the Baseline visit.
• A history of herpes (of any kind) in either eye.
• Cataract surgery and/or refractive surgery in either eye.
• Known contraindication, hypersensitivity, and/or allergy to any study drugs or excipients.
• Any acute illness (eg, acute infection) within 48 hours of first study drug administration, which is considered of significance by the Investigator.
• Participation in another clinical trial with drugs received within 30 days of Screening.
• Pregnant or currently lactating women.

Sponsors & Collaborators

• Orasis Pharmaceuticals Ltd.: lead

Study Sites (1)

The Department of Ophthalmology, Rambam Health Care Campus

Haifa, Israel

Location

MeSH Terms

Conditions

Presbyopia

Interventions

Macrophage Colony-Stimulating Factor

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Intervention Hierarchy (Ancestors)

Colony-Stimulating Factors; Glycoproteins; Glycoconjugates; Carbohydrates; Hematopoietic Cell Growth Factors; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Officials

• Eytan Blumental

  Head of Ophthalmology Department, Rambam Medical Center, Haifa, Israel

  STUDY DIRECTOR

• Andreja Veselica

  VID Medical Center, Nova Gorica, Slovenia

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2016
• First Posted: April 20, 2016
• Study Start: July 1, 2016
• Primary Completion: June 1, 2017
• Study Completion: June 1, 2017
• Last Updated: August 1, 2017

Record last verified: 2017-07

Locations

IL (1)